Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Cann Group ( (AU:CAN) ).
Cann Group Limited announced a correction to the Appendix 3X for Mr. Mike Ryan, who was appointed as a Director effective 1 December 2025. The initial filing omitted Mr. Ryan’s relevant interest in 2,608,696 ordinary shares, which were part of a capital raise. The correction ensures compliance with listing rules and highlights the company’s commitment to transparency.
The most recent analyst rating on (AU:CAN) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Cann Group stock, see the AU:CAN Stock Forecast page.
More about Cann Group
Cann Group Limited is a company dedicated to enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. It operates research facilities and corporate headquarters in Melbourne and has a large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. The company supplies a variety of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers both in Australia and internationally. Cann Group also owns Satipharm and its patent-protected capsule technology.
YTD Price Performance: -74.36%
Average Trading Volume: 3,900,024
Technical Sentiment Signal: Sell
Current Market Cap: A$10.06M
See more data about CAN stock on TipRanks’ Stock Analysis page.